'Immune reset' therapy puts severe lupus into remission in UK trial

A treatment that effectively resets a malfunctioning immune system has put severe lupus into remission for several patients in an early UK trial, raising hopes of a new approach to the long-term condition. The work was led by University College London Hospitals NHS Foundation Trust and University College London, two of the country's foremost centres for cell therapy research.

The trial used CAR T-cell therapy, in which a patient's own immune cells are genetically modified to recognise and remove the problem cells driving the disease. Until now the technique has mainly been used in cancer care on the NHS, where it has transformed outcomes for some patients with certain blood cancers.

Applying the approach to an autoimmune condition such as lupus represents a significant conceptual shift. Rather than targeting cancerous cells, the modified cells are directed at the immune cells responsible for the body attacking its own tissues, in effect rebooting the immune system so that it can rebuild without the faulty programming that drives the disease.

What the trial found

Nine patients aged between 12 and 65 with severe, treatment-resistant lupus were enrolled. These were people for whom existing therapies had failed to bring the disease under control, leaving them with limited options and, in some cases, serious complications affecting major organs.

Among those given a lower dose, five of six went into remission, with rapid improvements in disease markers over an average follow-up of around 11 months, including stabilised or improved kidney function in those with lupus nephritis. Kidney involvement is among the most dangerous features of severe lupus, so signs of recovery in that area were regarded by the team as especially encouraging.

Researchers were careful to frame the results as early and preliminary, drawn from a small number of patients over a relatively short period. Nonetheless, the speed and depth of the responses seen in those who entered remission marked the findings out as among the most promising in the field.

What the researchers say

Professor Karl Peggs of the UCLH biomedical research centre described the findings as groundbreaking and a source of fresh hope for people living with lupus. He stressed the importance of building carefully on the early results through larger and longer studies before the therapy could be considered for wider use.

Dr Claire Roddie of the UCL Cancer Institute said the therapy appeared able to reset the immune system and deliver meaningful clinical improvements. The crossover from cancer treatment to autoimmune disease, she noted, illustrated how advances in one area of medicine can open unexpected doors in another.

“We are seeing the immune system effectively reset, and with it, meaningful clinical improvements for patients who had run out of other options.”

— Dr Claire Roddie, UCL Cancer Institute

Background

Lupus is a chronic autoimmune condition in which the immune system mistakenly attacks healthy tissue, causing inflammation that can affect the skin, joints, kidneys and other organs. It can be highly unpredictable, with periods of relative calm interrupted by flares, and severe cases can be life-threatening. Existing treatments aim to suppress the immune system but do not cure the disease and can carry significant side effects.

CAR T-cell therapy has become one of the most celebrated advances in modern cancer care, offering durable responses for some patients with blood cancers who had exhausted other treatments. Extending the technology to autoimmune diseases has become an area of intense international research interest, with the prospect of a one-off treatment that could induce lasting remission representing a potential step change in how such conditions are managed.

• Trial size: nine patients aged 12 to 65 with severe, treatment-resistant lupus
• Outcome: among those on a lower dose, five of six went into remission
• Follow-up: an average of around 11 months, with improvements in disease markers
• Organ impact: stabilised or improved kidney function in patients with lupus nephritis
• Technique: CAR T-cell therapy, previously used mainly in NHS cancer care

Looking ahead

The results were presented at the EULAR European Congress of Rheumatology in London, one of the leading international gatherings for specialists in the field. Researchers said the same principle might in future be explored for other autoimmune illnesses, although larger studies will be needed before any wider conclusions can be drawn.

What it means

For patients with severe lupus who have exhausted conventional treatments, the early findings offer a genuine sense of hope, even as scientists urge caution about extrapolating too much from a small trial. The coming years will see researchers work to confirm the durability of the responses, understand which patients are most likely to benefit and assess the therapy's safety over the longer term. If the promise of these initial results holds, the approach could mark the beginning of a new chapter not only for lupus but for the treatment of autoimmune disease more broadly.